Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

HIGHLIGHTS

  • who: Carlos H. Barrios from the (UNIVERSITY) have published the research work: Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer, in the Journal: (JOURNAL) of 15/Nov/2021
  • what: The randomized, double-blind, phase III IMpassion031 study aimed to improve outcomes by adding the programmed deathligand 1 (PD-L1)-targeted checkpoint inhibitor atezolizumab to a neoadjuvant regimen of nab-paclitaxel followed by dose-dense doxorubicin plus cyclophosphamide6. The authors report results for prespecified PRO endpoints in the IMpassion031 study, investigating the impact of the addition of . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?